Pylopass Digestive-Health Ingredient Makes U.S. Debut
Pylopass, a digestive-health ingredient made from inactivated Lactobacillus reuteri cells, enters the U.S. market for the first time this month under the Life Extension brand.
Photo © iStockphoto.com/decade3d
Maypro Industries (Purchase, NY) announced this week that Pylopass, a digestive-health ingredient manufactured by German biotechnology company Organobalance, will be making its debut on the U.S. dietary supplements market. The ingredient, for which Maypro is the sole distributor, will be included in the supplement product Gastro-Ease under the Life Extension brand.
Pylopass was developed to combat the harmful stomach bacterium Helicobacter pylori, Maypro explains in the launch announcement, which is a gram-negative, spiral-shaped bacterium that can cause digestive-health issues by secreting enzymes that neutralize stomach acid. Maypro describes Pylopass as “a natural lactic acid bacterium from [Organobalance’s] microorganisms strain collection made from spray-dried inactivated cells of Lactobacillus reuteri,” which has been shown to reduce H. pylori counts. More than two-thirds of the world’s population is infected with H. pylori, Maypro notes, citing a report from the Center for Disease Control and Prevention (CDC).
“Pylopass has a unique effect against this carcinogenic stomach bacterium,” explains Christine Lang, PhD, microbiologist and managing director for Organobalance, in the launch announcement. “Unlike conventional therapies involving antibiotics which can harm the human microbiome, consumers who are taking Pylopass can lower their Helicobacter pylori load without losing their natural bacterial balance in their gut.”
While Pylopass is already on the market in many other countries, Life Extension is the first company to release a product with the ingredient on the U.S. market, Maypro adds. The shelf-stable ingredient is non-GMO and holds self-affirmed Generally Recognized as Safe (GRAS) status.
Read more:
Gut Check: Digestive-Health Market Update
Enzymes Broaden Reach Beyond Digestive Health
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
